By Professor Maria Kavallaris

Journal articles

Liu T, 2009, 'The cyclin-dependent kinase inhibitor, p21WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells', Carcinogenesis, 30, pp. 1865 - 1871, http://dx.doi.org/10.1093/carcin/bgp225

Raif A; Marshall GM; Bell J; Koach J; Tan O; D'andreti C; Thomas WD; Sekyere E; Norris MD; Haber M; Kavallaris M; Cheung BB, 2009, 'The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation', Cancer Letters, 277, pp. 82 - 90, http://dx.doi.org/10.1016/j.canlet.2008.11.030

Kavallaris M; Annereau JP; Barret JM, 2008, 'Potential Mechanisms of Resistance to Microtubule Inhibitors', Seminars in Oncology, 35, http://dx.doi.org/10.1053/j.seminoncol.2008.01.006

Ong V; Liem N; Schmid M; Verrills NM; Papa R; Marshall GM; Mackenzie K; Kavallaris M; Lock RB, 2008, 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', Journal of Pharmacology and Experimental Therapeutics, 324, pp. 434 - 442, http://dx.doi.org/10.1124/jpet.107.128926

Chan YK; Wong TH; Byrne F; Kavallaris M; Bulmus V, 2008, 'Acid-labile core cross-linked micelles for pH-triggered release of antitumor drugs.', Biomacromolecules, 9, pp. 1826 - 1836, http://dx.doi.org/10.1021/bm800043n

Liaw TY; Salam N; McKay M; Cunningham AM; Hibbs D; Kavallaris M, 2008, 'Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions', Molecular Cancer Therapeutics, 7, pp. 3150 - 3159

Michaud J; Simpson KM; Escher R; Buchet-Poyau K; Beissbarth T; Carmichael CA; Ritchie M; Schutz F; Cannon P; Liu M; Shen XF; Ito Y; Raskind WH; Horwitz MS; Osato M; Turner DR; Speed TP; Kavallaris M; Smyth GK; Scott HS, 2008, 'Integrative analysis of RUNX1 downstream pathways and target genes.', BMC Genomics, 8, pp. 363

Pasquier E; Kavallaris M, 2008, 'Microtubules: A dynamic target in cancer therapy', IUBMB Life, 60, pp. 165 - 170, http://dx.doi.org/10.1002/iub.25

Kavallaris M; Meachem S; Hulett M; West C; Pitt R; Chesters J; Laffan W; Boreham P; Khachigian LM, 2008, 'Perceptions in health and medical research careers: the Australian Society for Medical Research Workforce Survey', Medical Journal of Australia, 188, pp. 520 - 524

Gan PP; Kavallaris M, 2008, 'Tubulin-Targeted Drug Action: Functional Significance of Class II and Class IVb beta-Tubulin in Vinca Alkaloid Sensitivity', Cancer research, 68, pp. 9817 - 9824

Kavallaris M, 2007, 'Tubulin/microtubule system as an anti-cancer drug target', Current Cancer Drug Targets, 7, pp. 696, http://dx.doi.org/10.2174/156800907783220444

Escher R; Wilson P; Carmichael CA; Suppiah R; Liu M; Kavallaris M; Cannon P; Michaud J; Scott HS, 2007, 'A pedigree with autosomal dominant thrombocytopenia, red cell macrocytosis, and an occurrence of t(12:21) positive pre-B acute lymphoblastic leukemia', Blood Cells Molecules and Diseases, 39, pp. 107 - 114

Gan PP; Pasquier E; Kavallaris M, 2007, 'Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non-small cell lung cancer', Cancer research, 67, pp. 9356 - 9363

Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A, 2007, 'Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of Beta-tubulins', International Journal of Cancer, 120, pp. 2078 - 2085

Liaw TY; Chang MH; Kavallaris M, 2007, 'The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities', Current Drug Targets, 8, pp. 739 - 749

Butt A; Roberts CG; Seavvright A; Oelrichs P; Macleod JK; Liaw TY; Kavallaris M; Somers-Edgar T; Lehrbach GM; Watts CK; Sutherland RL, 2006, 'A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells', Molecular Cancer Therapeutics, 5, pp. 2300 - 2309

Chan YK; Bulmus V; Zareie MH; Barner L; Kavallaris M; Byrne F, 2006, 'Acid-Cleavable polymeric core-shell particles for delivery of hydrophoblic drugs', Journal of Controlled Release, 115, pp. 197 - 207

Pouha ST; Liu M; Marshall GM; Kavallaris M; Verrills NM, 2006, 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98, pp. 1363 - 1374

Kavallaris M, 2006, 'Discovering novel strategies for antimicrotubule cytotoxic therapy', EJC Supplements, 4, pp. 3 - 9, http://dx.doi.org/10.1016/j.ejcsup.2006.03.004

Verrills NM; Liaw TY; Lock RB; Kavallaris M; Liem N; Hood B, 2006, 'Proteomic anlaysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6, pp. 1681 - 1694

Cheung BB; Bell J; Raif A; Bohlken A; Yan J; Poljak A; Smith S; Lee M; Thomas WD; Kavallaris M; Norris MD; Haber M; Liu H; Zajchowski D; Marshall GM; bell , 2006, 'The estrogen-responsive B box protein is a novel regulator of the retinoid signal', The Journal of Biological Chemistry, 281, pp. 18246 - 18256

Verrills NM; Kavallaris M, 2005, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies', Current Pharmaceutical Design, 11, pp. 1719 - 1733

Verrills NM; Kavallaris M, 2005, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.', Current Pharmaceutical Design, 11, pp. 1719 - 1733

Kavallaris M; Marshall GM, 2005, 'Proteomics and disease: opportunities and challenges', Medical Journal of Australia, 182, pp. 575 - 579

Schevzov G; Vrhovski B; Bryce N; Elmir S; Qiu M; O''neill G; Yang N; Verrills N; Kavallaris M; Gunning P, 2005, 'Tissue-specific tropomyosin isoform composition.', Histochemical Journal, 53, pp. 557 - 570, http://dx.doi.org/10.1369/jhc.4A6505.2005

Don S; Verrills NM; Liaw T; Haber M; Norris MD; Kavallaris M, 2004, 'Neuronal-associated microtubule proteins class III B-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs.', Molecular Cancer Therapeutics, 3, pp. 1137 - 1146

Verrills NM; Kavallaris M, 2003, 'Drug Resistance Mechanisms in Cancer Cells: A Proteomics Perspective', Current Opinion in Molecular Therapeutics, 5, pp. 258 - 265

Burkhart CA; Cheng AJ; Madafiglio J; Kavallaris M; Mili M; Marshall GM; Weiss WA; Khachigian LM; Norris MD; Haber M, 2003, 'Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma', Journal of National Cancer Institute, 95, pp. 1394 - 1403

Cheung BB; Yan JX; Smith SA; Nguyen TG; Lee M; Kavallaris M; Norris MD; Haber M; Marshall GM, 2003, 'Growth inhibitory retinoid effects after recruitment of retinoid X receptor B to the retinoic acid receptor B promoter', International Journal of Cancer, 105, pp. 856 - 867

Verrills NM; Flemming C; Liu M; Ivery M; Cobon GS; Norris MD; Haber M; Kavallaris M, 2003, 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target', Chemistry and biology, 10, pp. 597 - 607

Verrills NM; Walsh B; Cobons GS; Hains P; Kavallaris M, 2003, 'Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukaemia reveals novel cytoskeletal alternations', The Journal of Biological Chemistry, 278, pp. 45082 - 45093

Kavallaris M; Verrills NM; Hill B, 2002, 'Anticancer therapy with novel tubulin-interacting drugs', Drug Resistance Updates, 4, pp. 392 - 401

Don S; Kavallaris M, 2002, 'Microtubule alterations and resostance to tubulin-binding agents', International Journal of Oncology, 21, pp. 621 - 628

Tait AS; Kavallaris M; etievant C; Unkown A; Barret J; Hill B, 2001, 'Markedly diminished drug-resistance including properties of vinflunine (20`, 20`- difluro- 3`, 4` - dihydrovinorelbine) relative tovinorelbine, identified in murine and human tumour cells in vivo and in vitro, with clinical implications', Cancer Chemotherapy and Pharmacology, pp. 62 - 70

Kavallaris M; Tait AS; Norris MD; Haber M; Walsh B; He L; Horwitz SB, 2001, 'Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells', Cancer research, pp. 5803 - 5809

Kavallaris M; Burkhart CA; Horwitz SB, 2001, 'The role of beta-tubulin isotypes in resistance to antimitotic drugs', Biochimica et Biophysica ACTA, 1471, pp. 1 - 9

Murphy KD; Ranganathan V; Farnsworth ML; Kavallaris M; Lock RB, 2000, 'Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumour cells', Cell death and differentiation, pp. 102 - 111

Haber M; Bordow SB; Gilbert J; Madafiglio J; Kavallaris M; Marshall GM; Mechetner EB; Fruehauf JP; Tee L; Cohn S; Salwen H; Schmidt ML; Norris MD; Gilbert J, 1999, 'Altered expression of the MYCN Oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells', Oncogene, 18, pp. 2777 - 2782

Kavallaris M; Burkhart CA; Horwitz SB, 1999, 'Antisense oligonucleotides to class III B-tubulin sensitise drug-resistant cells to Taxol.', British Journal of Cancer, pp. 1020 - 1025

Kavallaris M; Gardaneh M; Cheung BB; Camacho M; Hocker JE; Norris MD; Haber M; Marshall GM, 1998, 'In Vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells', Anticancer Research, pp. 1793 - 1798

Gifford AJ; Kavallaris M; Madafiglio J; Matherly LH; Stewart BW; Haber M; Norris MD, 1998, 'P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in Methotrexate accumulation due to a point mutation in the reduced folate carrier gene', International Journal of Cancer, pp. 176 - 181

Kavallaris M, 1997, 'The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance', Anti-Cancer Drugs, 8, pp. 17 - 25, http://dx.doi.org/10.1097/00001813-199701000-00002

Norris MD; Bordow SB; Haber PS; Marshall GM; Kavallaris M; Madafiglio J; Cohn S; Schmidt ML; Hipfner DR; Deeley RG; Cole SP; Haber M; Salwen H, 1997, 'EVIDENCE THAT THE N-MYC ONCOGENE REGULATES MRP GENE EXPRESSION IN NEUROBLASTOMA', European Journal of Cancer, pp. 1911 - 1916

Kavallaris M; Kuo DY; Burkhart CA; Regl DL; Norris MD; Haber M; Horwitz SB, 1997, 'TAXOL-RESISTANT EPITHELIAL OVARIAN TUMORS ARE ASSOCIATED WITH ALTERED EXPRESSION OF SPECIFIC {BETA}-TUBLIN ISOTYPES', Journal of Clinical Investigation, 100, pp. 1282 - 1293

Kavallaris M; Leary JA; Barrett JA; Friedlander ML, 1996, 'MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors', Cancer Letters, 102, pp. 7 - 16, http://dx.doi.org/10.1016/0304-3835(96)04143-2

Norris MD; De Graaf D; Haber M; Kavallaris M; Madafiglio J; Gilbert J; Kwan E; Stewart BW; Mechetner EB; Gudkov AV; Roninson IB, 1996, 'Involvement of MDR1 P-Glycoprotein in multifactorial resistance to methotrexate', International Journal of Cancer, pp. 613 - 619

Haber M; Norris MD; Kavallaris M; Camacho M; Madafiglio J; Baker C; White L; Stewart BW, 1995, 'An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro', Cancer Letters, pp. 49 - 55

Norris MD; Haber M; Gilbert J; Kavallaris M; Marshall GM; Stewart BW, 1994, 'N-myc gene amplification in neuroblastoma determined by the polymerase chain reaction.', Progress in clinical and biological research, 385, pp. 27 - 33

Gilbert J; Norris MD; Haber M; Kavallaris M; Marshall GM; Stewart BW, 1993, 'Determination of n-myc gene amplification in neuroblastoma by differential polymerase chain reaction', Molecular and Cellular Probes, 7, pp. 227 - 234, http://dx.doi.org/10.1006/mcpr.1993.1033

Pittman SM; Kavallaris M; Stewart BW, 1993, 'Karyotypic analysis of CCRF-CEM and drug-resistant cell lines with stable and unstable ploidy', Cancer Genetics and Cytogenetics, 66, pp. 54 - 62, http://dx.doi.org/10.1016/0165-4608(93)90149-G

Back to profile page